ImmunityBio, Inc.

NASDAQ:IBRX

Biotechnology

Healthcare
$6.70 +2.58%

+$0.18 today

Market cap
$7.13B
Beta
0.10
P/E (TTM)
-8.6
EPS (TTM)
-$0.83
52W Low $1.95High $12.43

Volume 15.77M

Average 16.40M

IBRX Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

ImmunityBio, Inc.NASDAQ: IBRX

Gross Margin · Q3 FY2026 · quarter ended Sep 2026

Gross margin widens to 97.4%

Gross margin was 97.4% in Q3 FY2026, up 10.2 pp from a year earlier. On a trailing-twelve-month basis it was 96.7%, up 1.9 pp year over year. Over 3 fiscal years it narrowed by 0.7 pp.

Context

  • Gross margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
97.4%-2.1 pp QoQ
Last fiscal yearDec 2025
99.3%-0.7 pp YoY
LTMSep 2026
96.7%+1.9 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+10.2 pp——
1 year-0.7 pp——
3 years-0.7 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
99.3%
Year-over-year change
-0.7pp

Gross Margin vs competitors

How IBRX compares with its peers on the latest reported figures

  • IBRX's LTM Sep 2026 gross margin of 96.7% is the 4th highest of the 9 companies compared; the peer median is 83.5%.
  • Its year-over-year change of +1.9 pp is the 5th highest of 9, against a peer median of +8.0 pp.
  • Over three fiscal years its change of -0.7 pp compares with a peer median of +16.2 pp.
IBRX Competitors Peer median
Gross Margin for IBRX and competitors
Company Period LTM level YoY 3-year change
VIRVir Biotechnology, Inc.LTM Mar 2026275.2% +2604.6 pp+21.4 pp
IMTXImmatics N.V.LTM Mar 2026100.0% +0.1 pp+61.8 pp
IMCRImmunocore Holdings plcLTM Mar 202698.8% -0.2 pp+1.6 pp
IBRXImmunityBio, Inc.LTM Sep 202696.7% +1.9 pp-0.7 pp
ATRAAtara Biotherapeutics, Inc.LTM Mar 202696.1% +15.9 pp+407.1 pp
BNTXBioNTech SELTM Jun 202670.8% -8.9 pp-5.1 pp
LEGNLegend Biotech CorporationLTM Sep 202657.0% -3.6 pp+16.2 pp
IOVAIovance Biotherapeutics, Inc.LTM Sep 202653.2% +23.4 pp—
MRNAModerna, Inc.LTM Sep 202628.0% +16.1 pp-16.0 pp
ALLOAllogene Therapeutics, Inc.FY2025— ——
NKTXNkarta, Inc.FY2025— ——
Peer median (excluding IBRX) 83.5%+8.0 pp+16.2 pp

Competitors are the stored peer set for IBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue934K240K622K14.75M113.29M
Cost of Revenue0000753K
Gross Profit934K240K622K14.75M112.54M
Gross Margin100.0%100.0%100.0%100.0%99.3%
Research & Development195.96M248.15M232.37M190.14M207.88M
Selling, General & Admin135.26M102.71M129.62M168.78M147.18M
Operating Expenses331.21M351.54M362.87M358.93M368.56M
Depreciation & Amortization14.24M18.26M18.51M17.55M15.53M
EBITDA(320.75M)(351.88M)(478.66M)(264.43M)(223.56M)
EBITDA Margin-34341.8%-146617.1%-76955.5%-1793.4%-197.3%
Operating Income(330.28M)(351.3M)(362.25M)(344.18M)(256.03M)
Operating Margin-35361.9%-146374.2%-58239.5%-2334.2%-226.0%
Interest Income836K2.71M863K2.4M6.7M
Interest Expense14.85M47.15M86.72M131.66M112.53M
Other Income / Expenses(19.56M)(65.99M)(221.64M)(69.46M)(95.58M)
Income Before Tax(349.84M)(417.29M)(583.89M)(413.65M)(351.61M)
Pre-Tax Margin-37456.0%-173869.2%-93873.3%-2805.3%-310.4%
Income Tax Expense9K34K(40K)0(135K)
Net Income(346.79M)(416.57M)(583.2M)(413.56M)(351.4M)
Net Margin-37129.6%-173569.6%-93761.4%-2804.8%-310.2%
EPS (Basic)(0.89)(1.04)(1.15)(0.59)(0.38)
EPS (Diluted)(0.89)(1.04)(1.15)(0.62)(0.38)
Weighted Avg Shares389.23M399.9M508.64M697.31M919.86M
Weighted Avg Shares (Diluted)389.23M399.9M508.64M700.44M919.86M

ImmunityBio, Inc.

NASDAQ:IBRX

Intrinsic Alpha fair value

Locked

Current Price

$6.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.